Nicotinamide Mononucleotide — Safety, Research, Risks & Legal Status

Not medical advice. Nicotinamide Mononucleotide is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	NMN, NAD+ precursor
Category	Supplement
dad_precursor	True
preclinical_lifespan_extension	True
human_trials_limited	True
bioavailability_challenge	poor oral absorption
US legal status	Sold as a dietary supplement in the USA under DSHEA. Not FDA-approved as a drug. Purity and potency vary widely by manufacturer. No prescription required; available over-the-counter.

What is Nicotinamide Mononucleotide?

A nucleotide and direct NAD+ precursor involved in cellular energy metabolism and mitochondrial function. Intracellular NAD+ levels decline with age; exogenous NMN supplementation aims to restore NAD+ pools and support metabolic health.

How it works

NMN is a direct NAD+ precursor bypassing the salvage pathway via phosphoribosyl transferase. NAD+ is cofactor for sirtuins (SIR1-7, metabolic/stress response), PARPs (DNA repair), and CD38 (immune regulation). Age-related NAD+ decline affects all these pathways.

Background & history

NAD+ metabolism rediscovered in aging research ~2009-2010 (Sinclair lab). NMN developed as NAD+ supplement candidate; clinical trials began ~2016. Still early-stage with limited human data compared to NR.

What the research says

Preclinical rodent studies report improvements in mitochondrial function, metabolic rate, and lifespan-extension markers. Limited human trials; small studies suggest improved exercise capacity and metabolic markers in healthy older adults. Evidence is mixed and sample sizes are small; translation to humans is preliminary.

Reported effects

Studied for increased NAD+ levels and mitochondrial ATP production
Preclinical evidence for improved metabolic rate and exercise capacity
Research suggests potential anti-aging effects (animal models only)
Small human studies report improved insulin sensitivity markers
Proposed sirtuin activation and PARP1 support
Potential enhanced mitochondrial biogenesis in animal models

Dosing & administration (informational)

Animal studies use high doses (500-1000 mg/kg). Human trials range 250-1000 mg daily, typically taken orally. No optimal human dose established; bioavailability limits absorption.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Well-tolerated in short-term human studies (weeks to months)
Nausea reported at high doses
Long-term safety in humans not established; studies typically 4-12 weeks
Potential interaction with NAD+-consuming enzymes (sirtuins, PARPs) unclear
Purity and bioavailability vary greatly by product; many lack third-party testing
Risk of GI upset and flushing at high doses

Drug & supplement interactions

Sirtuin activators (resveratrol): potential synergistic or antagonistic effects unknown
Metformin: both affect AMPK pathway; interaction not fully characterized
NAD+-consuming drugs (PARPi inhibitors): potential reduced efficacy
Fasting and caloric restriction: both increase NAD+; additive effects unknown
Statin drugs: may affect NAD+ metabolism via mitochondrial pathways

Who should avoid it

Severely compromised liver or kidney function
Ongoing cancer treatment (NAD+-dependent pathways in cancer cells)
Active infection with compromised immunity (NAD+ role in immune regulation)
Pregnancy (insufficient safety data)
Combination with unapproved supplements of unknown composition

How it is commonly combined

NMN stacking with other NAD+ precursors (NR, tryptophan, niacin) is redundant and untested; concurrent use not recommended. May stack with AMPK activators (metformin) or sirtuin-supporting compounds (resveratrol) but efficacy uncertain.

Legal & regulatory. Sold as a dietary supplement in the USA under DSHEA. Not FDA-approved as a drug. Purity and potency vary widely by manufacturer. No prescription required; available over-the-counter.

Quality & harm reduction

T
h
i
r
d
-
p
a
r
t
y
C
O
A
(
C
e
r
t
i
f
i
c
a
t
e
o
f
A
n
a
l
y
s
i
s
)
c
r
i
t
i
c
a
l
;
v
e
r
i
f
y
p
u
r
i
t
y
g
r
e
a
t
e
r
t
h
a
n
9
8
%
.
B
i
o
a
v
a
i
l
a
b
i
l
i
t
y
v
a
r
i
e
s
b
y
f
o
r
m
;
s
t
a
n
d
a
r
d
p
o
w
d
e
r
i
s
c
o
m
m
o
n
l
y
a
d
u
l
t
e
r
a
t
e
d
.
L
o
o
k
f
o
r
G
M
P
c
e
r
t
i
f
i
c
a
t
i
o
n
a
n
d
r
e
p
u
t
a
b
l
e
s
u
p
p
l
i
e
r
;
m
a
n
y
r
e
d
f
l
a
g
s
f
o
r
e
x
a
g
g
e
r
a
t
e
d
l
o
n
g
e
v
i
t
y
c
l
a
i
m
s
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does NMN actually increase NAD+ in humans?

Small human studies suggest increased blood NAD+ after NMN dosing, but tissue-level NAD+ improvement and functional benefit are not proven.

Is NMN better than nicotinamide riboside (NR)?

Both are NAD+ precursors; limited head-to-head human trials. NR has more clinical data. Relative efficacy unclear.

What dose is effective?

Animal studies use high doses (500-1000 mg/kg); human trials range widely (250-1000 mg/day). No optimal human dose established.

Can NMN extend lifespan?

Lifespan extension is only shown in rodent models. No human longevity data exists. Use of NMN for life extension is speculative.

What about bioavailability concerns?

NMN has poor oral bioavailability; may be degraded in GI tract. Newer formulations attempt to address absorption but clinical evidence is limited.

References & further reading

Sinclair et al. aging and NAD+ metabolism reviews
Human NMN clinical trials (Washington University, Keio University, others)
NAD+-dependent enzyme biology and pharmacology literature
Supplement maker quality assessments and third-party testing data